| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 1965 | 2010 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 607 | 2014 |
| Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial … R Gralla, M Lichinitser, S Van Der Vegt, H Sleeboom, J Mezger, ... Annals of Oncology 14 (10), 1570-1577, 2003 | 574 | 2003 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 565 | 2009 |
| Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr) E Cacciari, S Milani, A Balsamo, E Spada, G Bona, L Cavallo, F Cerutti, ... Journal of endocrinological investigation 29 (7), 581-593, 2006 | 565 | 2006 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... | 475 | 2005 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 466 | 2009 |
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 450 | 2015 |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ... Clinical Cancer Research 9 (8), 2893-2897, 2003 | 364 | 2003 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 341 | 2007 |
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ... Clinical Cancer Research 8 (5), 1080-1084, 2002 | 317 | 2002 |
| Italian cross-sectional growth charts for height, weight and BMI (6–20 y) E Cacciari, S Milani, A Balsamo, F Dammacco, F De Luca, F Chiarelli, ... European Journal of Clinical Nutrition 56 (2), 171-180, 2002 | 310 | 2002 |
| Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini Journal of clinical pathology 57 (6), 591-597, 2004 | 262 | 2004 |
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 261 | 2008 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 205 | 2017 |
| The antineoplastic role of bisphosphonates: from basic research to clinical evidence D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ... Annals of Oncology 14 (10), 1468-1476, 2003 | 200 | 2003 |
| Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in … D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ... Clinical Cancer Research 13 (15), 4482-4486, 2007 | 192 | 2007 |
| Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ... European journal of cancer 44 (13), 1875-1882, 2008 | 189 | 2008 |
| Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ... J Clin Oncol 24 (12), 1883-1891, 2006 | 177 | 2006 |
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ... The oncologist 15 (1), 85, 2010 | 176 | 2010 |
